Cargando…
Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents
Background: Biodegradable polymer (BP) drug-eluting stents (DES) have been introduced as a novel solution to the problems of durable polymer (DP) stents. In Pakistan, very few studies are available for the treatment intervention in post-primary percutaneous coronary intervention (PPCI) patients. Our...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709248/ https://www.ncbi.nlm.nih.gov/pubmed/36467026 http://dx.doi.org/10.3389/fphar.2022.900798 |
_version_ | 1784841107300941824 |
---|---|
author | Bibi, Salma Khan, Amjad Khan, Amer Hayat Khan, Muhammad Niaz Mushtaq, Saima Rashid, Sheikh Abdur |
author_facet | Bibi, Salma Khan, Amjad Khan, Amer Hayat Khan, Muhammad Niaz Mushtaq, Saima Rashid, Sheikh Abdur |
author_sort | Bibi, Salma |
collection | PubMed |
description | Background: Biodegradable polymer (BP) drug-eluting stents (DES) have been introduced as a novel solution to the problems of durable polymer (DP) stents. In Pakistan, very few studies are available for the treatment intervention in post-primary percutaneous coronary intervention (PPCI) patients. Our study will compare the major adverse cardiovascular events (MACEs) and their predictors in patients with coronary artery disease (CAD) undergoing PPCI with second- or third-generation DES. Methodology: An observational, retrospective, cohort study was carried out on CAD patients undergoing PPCI with either second- (DP-XIENCE Prime/XIENCE Xpedition) or third-generation (BP-BioMatrix NeoFlex/BioMatrix Alpha) DES. MACEs were assessed after 1 year of PPCI procedure in 341 patients and screened as per inclusion/exclusion criteria (167 in the second-generation group and 174 in the third-generation group). Results: The number of male patients (86.2%) was more than female patients in our study population. MACEs were reported in 4.19% patients after 1 year duration, and the percentage of MACEs was more in the second-generation DES group (4.77%) than in the third-generation group (3.44%); however, statistical analysis has not found any significant difference (p = 0.534). The rate of myocardial infarction (1.19% vs. 0.57%) and stent thrombosis (1.8% vs. 1.15%) was more in the second-generation DES group. However, restenosis (1.19% vs. 1.15%) and cardiac death (0.59% vs. 0.57%) were almost same in both groups. A significant association was found between MACEs and diabetes mellitus (p = 0.025), hypertension (p = 0.035), smoking (p = 0.008), and a family history of CAD (p = 0.018). Conclusion: BP-BioMatrix and DP-XIENCE DES have comparable clinical outcomes. Findings of the current study will assist the policy makers and healthcare providers in the rationalization of scarce resources and evidence-based patient care. However, longer follow-up studies are required for convincing results. |
format | Online Article Text |
id | pubmed-9709248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97092482022-12-01 Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents Bibi, Salma Khan, Amjad Khan, Amer Hayat Khan, Muhammad Niaz Mushtaq, Saima Rashid, Sheikh Abdur Front Pharmacol Pharmacology Background: Biodegradable polymer (BP) drug-eluting stents (DES) have been introduced as a novel solution to the problems of durable polymer (DP) stents. In Pakistan, very few studies are available for the treatment intervention in post-primary percutaneous coronary intervention (PPCI) patients. Our study will compare the major adverse cardiovascular events (MACEs) and their predictors in patients with coronary artery disease (CAD) undergoing PPCI with second- or third-generation DES. Methodology: An observational, retrospective, cohort study was carried out on CAD patients undergoing PPCI with either second- (DP-XIENCE Prime/XIENCE Xpedition) or third-generation (BP-BioMatrix NeoFlex/BioMatrix Alpha) DES. MACEs were assessed after 1 year of PPCI procedure in 341 patients and screened as per inclusion/exclusion criteria (167 in the second-generation group and 174 in the third-generation group). Results: The number of male patients (86.2%) was more than female patients in our study population. MACEs were reported in 4.19% patients after 1 year duration, and the percentage of MACEs was more in the second-generation DES group (4.77%) than in the third-generation group (3.44%); however, statistical analysis has not found any significant difference (p = 0.534). The rate of myocardial infarction (1.19% vs. 0.57%) and stent thrombosis (1.8% vs. 1.15%) was more in the second-generation DES group. However, restenosis (1.19% vs. 1.15%) and cardiac death (0.59% vs. 0.57%) were almost same in both groups. A significant association was found between MACEs and diabetes mellitus (p = 0.025), hypertension (p = 0.035), smoking (p = 0.008), and a family history of CAD (p = 0.018). Conclusion: BP-BioMatrix and DP-XIENCE DES have comparable clinical outcomes. Findings of the current study will assist the policy makers and healthcare providers in the rationalization of scarce resources and evidence-based patient care. However, longer follow-up studies are required for convincing results. Frontiers Media S.A. 2022-11-16 /pmc/articles/PMC9709248/ /pubmed/36467026 http://dx.doi.org/10.3389/fphar.2022.900798 Text en Copyright © 2022 Bibi, Khan, Khan, Khan, Mushtaq and Rashid. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Bibi, Salma Khan, Amjad Khan, Amer Hayat Khan, Muhammad Niaz Mushtaq, Saima Rashid, Sheikh Abdur Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents |
title | Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents |
title_full | Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents |
title_fullStr | Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents |
title_full_unstemmed | Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents |
title_short | Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents |
title_sort | primary percutaneous coronary intervention in cad patients: a comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709248/ https://www.ncbi.nlm.nih.gov/pubmed/36467026 http://dx.doi.org/10.3389/fphar.2022.900798 |
work_keys_str_mv | AT bibisalma primarypercutaneouscoronaryinterventionincadpatientsacomparisonofmajoradversecardiovasculareventsofsecondandthirdgenerationdrugelutingstents AT khanamjad primarypercutaneouscoronaryinterventionincadpatientsacomparisonofmajoradversecardiovasculareventsofsecondandthirdgenerationdrugelutingstents AT khanamerhayat primarypercutaneouscoronaryinterventionincadpatientsacomparisonofmajoradversecardiovasculareventsofsecondandthirdgenerationdrugelutingstents AT khanmuhammadniaz primarypercutaneouscoronaryinterventionincadpatientsacomparisonofmajoradversecardiovasculareventsofsecondandthirdgenerationdrugelutingstents AT mushtaqsaima primarypercutaneouscoronaryinterventionincadpatientsacomparisonofmajoradversecardiovasculareventsofsecondandthirdgenerationdrugelutingstents AT rashidsheikhabdur primarypercutaneouscoronaryinterventionincadpatientsacomparisonofmajoradversecardiovasculareventsofsecondandthirdgenerationdrugelutingstents |